FDA Approved: EMFLAZA — Supplemental Application (PTC Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for EMFLAZA (deflazacort) from PTC Therapeutics, expanding/confirming its labeling for Duchenne muscular dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• EMFLAZA (deflazacort)

Snippet

SUPPL AP for EMFLAZA (DEFLAZACORT)